惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Hugging Face - Blog
Hugging Face - Blog
量子位
H
Help Net Security
Microsoft Azure Blog
Microsoft Azure Blog
MongoDB | Blog
MongoDB | Blog
小众软件
小众软件
爱范儿
爱范儿
博客园 - 【当耐特】
Vercel News
Vercel News
S
SegmentFault 最新的问题
M
MIT News - Artificial intelligence
F
Fortinet All Blogs
Apple Machine Learning Research
Apple Machine Learning Research
GbyAI
GbyAI
博客园 - 叶小钗
博客园_首页
V
Visual Studio Blog
宝玉的分享
宝玉的分享
B
Blog
MyScale Blog
MyScale Blog
C
Check Point Blog
博客园 - 三生石上(FineUI控件)
L
LangChain Blog
V
V2EX

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Merck KGaA: Small Breakout In 2026, Followed By Normaliza...
2026-04-27 · via All Articles on Seeking Alpha

Summary

  • Merck KGaA is rated a 'Buy' with a revised price target of €127/share, reflecting strong fundamentals and resilient business segments.
  • I expect 2026 to be a transition year with AEPS decline due to divestments, FX headwinds, and muted guidance, but I see robust growth potential beyond.
  • MKGAF's diversified pharma, life science, and electronics segments provide insulation against patent cliffs and biopharma volatility, supporting long-term stability.
  • Valuation at 15–18x P/E suggests 12–19% annual returns, with low leverage and an A rating underpinning the investment case despite near-term challenges.
  • I do much more than just articles at Wolf of Value: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Empty stage construction at festival

Wirestock/iStock Editorial via Getty Images

Merck KGaA (MKGAF), that's the European Merck, not the US-based Merck (MRK), is a company I have been covering and also investing in for some time. In a previous article, about

35.19K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MKGAF, SNY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment. Short-term trading, options trading/investment, and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding of the necessary risk tolerance involved. I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about. Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.